Widely used:Recently Viewed
Clear All
$69.63
$0.00 (0.00%)As on 04-Oct-2024 16:00 EDT
$3,548 Mln
--
5.53
87.36
0
-0.27 %
--
--
--
-26747
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Axonics Modulation Technologies Inc (AXNX)
| 11.89 | 0.68 | 3.13 | 25.96 | 1.38 | 21.29 | -- |
|
BSE Sensex
| 13.08 | -1.05 | 2.13 | 24.69 | 11.60 | 16.47 | 11.89 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
|
|---|---|---|---|---|---|
|
Axonics Modulation Technologies Inc (AXNX)
| -0.48 | 11.66 | 12.18 | 80.15 | 83.39 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Our rating system has guided millions of investors in the past 20 years.
$3,548.11 Mln
$408.81 Mln
$3.93 Mln
$343.41 Mln
$32.45 Mln
High
$48.30 - 69.91
51,118,100
NASDAQ: AXNX
Irvine, CA
https://www.axonics.com
Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive... bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California. Address: 26 Technology Drive, Irvine, CA, United States, 92618 Read more
The total asset value of Axonics Modulation Technologies Inc (AXNX) stood at $ 805 Mln as on 30-Jun-24
The share price of Axonics Modulation Technologies Inc (AXNX) is $69.63 (NASDAQ) as of 04-Oct-2024 16:00 EDT. Axonics Modulation Technologies Inc (AXNX) has given a return of 1.38% in the last 3 years.
Axonics Modulation Technologies Inc (AXNX) has a market capitalisation of $ 3,548 Mln as on 02-Oct-2024. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Axonics Modulation Technologies Inc (AXNX) is 5.53 times as on 02-Oct-2024, a 26% premium to its peers’ median range of 4.38 times.
Since, TTM earnings of Axonics Modulation Technologies Inc (AXNX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Axonics Modulation Technologies Inc (AXNX) and enter the required number of quantities and click on buy to purchase the shares of Axonics Modulation Technologies Inc (AXNX).
Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California. Address: 26 Technology Drive, Irvine, CA, United States, 92618
The CEO & director of Mr. Raymond W. Cohen. is Axonics Modulation Technologies Inc (AXNX), and CFO & Sr. VP is Mr. Raymond W. Cohen.
There is no promoter pledging in Axonics Modulation Technologies Inc (AXNX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,011
|
|
|
953
|
|
|
937
|
|
|
912
|
| Axonics Modulation Technologies Inc (AXNX) | Ratios |
|---|---|
|
Return on equity(%)
|
-0.27
|
|
Operating margin(%)
|
0.36
|
|
Net Margin(%)
|
-0.42
|
|
Dividend yield(%)
|
--
|
Yes, TTM profit after tax of Axonics Modulation Technologies Inc (AXNX) was $4 Mln.
